Thymosin Alpha-1 5mg
Thymic Immune Modulator for Infection and Cancer Research
Thymosin Alpha-1 (Thymalfasin) is FDA-approved as Zadaxin and used in over 35 countries for hepatitis B/C, immune deficiency, and cancer treatment. It activates dendritic cells, enhances T-cell proliferation, and restores immune competence in compromised patients.
Thymic Immune Modulator for Infection and Cancer Research
TA-1 is a 28-amino acid thymic peptide that matures and activates T-lymphocytes, enhances NK cell activity, stimulates dendritic cell maturation, and upregulates MHC class I expression on tumor cells — making them more visible to immune surveillance.
As one of the most studied compounds in the recovery & healing research space, TA-1 has attracted sustained scientific interest across Immune modulation research, Viral infection studies, Cancer immunotherapy research. Peer-reviewed evidence indicates that fDA-approved (Zadaxin) for hepatitis and immunodeficiency, which has positioned TA-1 as a reference standard for researchers exploring immune modulation research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
TA-1 Documented Benefits: 4 Documented Mechanisms
T-Cell Activation
Matures naive T-cells and enhances cytotoxic T-lymphocyte proliferation against viral and tumor targets.
Dendritic Cell Maturation
Enhances antigen presentation by promoting dendritic cell differentiation and activation.
NK Cell Enhancement
Increases natural killer cell cytotoxicity for improved innate immune tumor surveillance.
Antiviral Activity
Reduces hepatitis B/C viral load in clinical studies; FDA-approved in multiple countries.
How TA-1 Works: Molecular Mechanism & Pathway
Thymic peptide activating TLR2/9 on dendritic cells, promoting T-helper 1 polarization, and enhancing cytotoxic immune responses via NF-κB and MAPK pathways.
The 4 primary research pathways identified for TA-1 — T-Cell Activation, Dendritic Cell Maturation, NK Cell Enhancement — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that enhances vaccine efficacy in clinical trials, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, TA-1's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
TA-1 is routinely studied alongside LL-37 and TA-1 in recovery & healing-focused compound panels. Researchers investigating immune modulation research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that reduces cancer-related immunosuppression in studies has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All TA-1 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- FDA-approved (Zadaxin) for hepatitis and immunodeficiency
- Enhances vaccine efficacy in clinical trials
- Reduces cancer-related immunosuppression in studies
Ideal For
- Immune modulation research
- Viral infection studies
- Cancer immunotherapy research
- Vaccine adjuvant studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on TA-1. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
FDA-approved (Zadaxin) for hepatitis and immunodeficiency
Enhances vaccine efficacy in clinical trials
Reduces cancer-related immunosuppression in studies
Third-Party Verified Every Batch
Each vial of TA-1 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
